Guinness Asset Management LTD Buys New Shares in Medtronic PLC $MDT

Guinness Asset Management LTD purchased a new position in Medtronic PLC (NYSE:MDT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,932,387 shares of the medical technology company’s stock, valued at approximately $275,556,000. Medtronic makes up 4.4% of Guinness Asset Management LTD’s holdings, making the stock its 4th largest holding. Guinness Asset Management LTD owned 0.23% of Medtronic as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. MONECO Advisors LLC boosted its stake in shares of Medtronic by 13.4% in the third quarter. MONECO Advisors LLC now owns 6,835 shares of the medical technology company’s stock worth $651,000 after acquiring an additional 808 shares during the period. Waterloo Capital L.P. raised its stake in Medtronic by 44.7% during the 3rd quarter. Waterloo Capital L.P. now owns 3,636 shares of the medical technology company’s stock valued at $346,000 after purchasing an additional 1,123 shares during the period. Firestone Capital Management purchased a new position in Medtronic in the 3rd quarter worth approximately $200,000. Portside Wealth Group LLC lifted its holdings in Medtronic by 0.8% in the 3rd quarter. Portside Wealth Group LLC now owns 39,022 shares of the medical technology company’s stock worth $3,716,000 after purchasing an additional 323 shares in the last quarter. Finally, Altrius Capital Management Inc boosted its stake in Medtronic by 1.2% in the 3rd quarter. Altrius Capital Management Inc now owns 54,590 shares of the medical technology company’s stock worth $5,199,000 after purchasing an additional 662 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Daiwa Capital Markets raised their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. TD Cowen reiterated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Citigroup initiated coverage on shares of Medtronic in a report on Tuesday. They set a “buy” rating and a $117.00 price objective for the company. Finally, Sanford C. Bernstein lifted their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.67.

Medtronic Stock Up 1.1%

Shares of NYSE MDT opened at $102.92 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm’s 50-day moving average price is $99.44 and its 200-day moving average price is $96.01. The stock has a market capitalization of $131.95 billion, a price-to-earnings ratio of 27.74, a P/E/G ratio of 2.68 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts remain constructive — several outlets highlight bullish analyst views on Medtronic, supporting confidence in longer‑term growth prospects. Analysts Are Bullish on These Healthcare Stocks: Medtronic (MDT)
• Positive Sentiment: Product/market expansion — coverage notes Medtronic is broadening its heart and diabetes tools and integrating new offerings, which can support revenue growth and investors’ valuation assumptions. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Positive Sentiment: Strategic M&A — Medtronic expanded its cath lab portfolio with the CathWorks acquisition, strengthening structural/cath lab offerings and cross‑sell opportunities. That helps offset competitive pressure in some device categories. Medtronic expands cath lab portfolio with CathWorks acquisition
• Neutral Sentiment: New analyst coverage — Citigroup began coverage of MDT, which can increase analyst attention and trading liquidity; the ultimate impact depends on the published rating and target. Citigroup Begins Coverage on Medtronic (NYSE:MDT)
• Neutral Sentiment: Valuation and investor commentary are mixed — several pieces debate whether recent gains leave MDT reasonably priced; these discussions can moderate momentum but don’t directly change fundamentals. Is Medtronic (MDT) Still Reasonably Priced After Recent Share Price Gains?
• Neutral Sentiment: Leadership change — the president of Structural Heart, Nina Goodheart, is retiring; this is notable for execution risk in that business but not an immediate financial shock. Medtronic Structural Heart President Nina Goodheart to retire
• Neutral Sentiment: Market performance context — one note shows MDT outperformed intraday but underperformed peers on the day, signaling relative-strength questions even amid gains. Medtronic PLC stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: Major legal setback — a U.S. jury found Medtronic unlawfully monopolized the market for certain vessel‑sealing devices and ordered roughly $382 million in damages to Applied Medical; this is the most immediate negative catalyst and creates financial, reputational and potentially precedent risks. Medtronic owes $382 million to medical device rival in antitrust lawsuit, US jury says Applied Medical Prevails in Antitrust Jury Trial Against Medtronic

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).